骨髓靶向柔红霉素毫微粒的研究  

Study on Bone Marrow Targeting Daunorubicin Polybutylcyanoacrylate Nanoparticles

作　　者：彭应旭[1] 庄燕黎[1] 廖工铁[2] 

机构地区：[1]上海医药工业研究院制剂室,上海200437 [2]华西医科大学药学院,四川成都610041

出　　处：《中国医药工业杂志》2000年第2期57-61,共5页Chinese Journal of Pharmaceuticals

摘　　要：采用乳液聚合法制备了柔红霉素聚氰基丙烯酸正丁酯毫微粒(1),并对其形态、粒径及分布、载药性、动物体内经时变化过程及骨髓靶向性进行了研究。结果表明1平均粒径为70nm,分布范围30～220nm,包封率为97.0%,载药量达55.7%(g/g);小鼠尾静脉注射相同剂量1及柔红霉素后,前者股骨内峰浓度提高到1.62倍,AUC提高到4.87倍,总靶向效率从5.17%提高至24.19%,表明1具骨髓靶向性。The bone marrow targeting daunorubicin polybutylcyanoacrylate nanoparticles (1,DNR PBCA NP) were prepared by emulsion polymerization.The morphology,size and size distribution and drug loading of 1 lyophilization injection were studied.The results showed that the median diameter of 1 was 70 nm with the range of 30~220 nm.The association ratio was 97.0% and the drug loading was 55.7%(g/g).The tissue distribution and the bone marrow targeting characteristics of 1 and DNR injection after intravenous injection in mice were studied by HPLC.The results showed that the C max of 1 in bone marrow was increased to 1.62 fold and its AUC was increased to 4.87 fold.The overall targeting efficiency ( Te ) in the bone marrow was increased from 5.17% to 24.19%.\;

关 键 词：柔红霉素 毫微粒 DNR-PBCA-NP 骨髓靶向性 

分 类 号：R979.14[医药卫生—药品] R944.9[医药卫生—药学]